Beyond DNA: Illumina’s New Multi-Omics Play

Illumina completes its SomaLogic acquisition, expanding beyond DNA sequencing into integrated, end-to-end multi-omics drug discovery

3 Mar 2026

Illumina has completed its $350mn acquisition of SomaLogic, marking an expansion beyond DNA sequencing into the growing field of protein analysis as pharmaceutical companies seek broader biological insight in drug development.

The deal, finalised on January 30, was paid in cash at closing with additional performance-based milestones. It signals a strategic shift for the US biotechnology group, which has built its business around large-scale gene sequencing platforms used by research laboratories worldwide.

While genomics has transformed biomedical research, drugmakers continue to face high clinical failure rates and rising development costs. Industry executives increasingly argue that genetic data alone offers an incomplete picture of disease.

Proteins, which reflect how genes function inside the body, can provide more immediate insight into disease processes. By incorporating SomaLogic’s protein measurement technology, Illumina aims to link genetic information with protein data, creating a broader “multi-omics” platform that integrates different layers of biological analysis.

The acquisition builds on an existing partnership. The two companies have worked together since 2021 to develop proteomic tools compatible with Illumina’s sequencing systems. That collaboration is expected to ease technical integration and speed commercial rollout.

The transaction positions Illumina as a more comprehensive supplier to pharmaceutical and biotechnology groups, which increasingly prefer to reduce the number of technology vendors and streamline data management. Offering both genomic and proteomic capabilities under one platform may strengthen Illumina’s appeal as an end-to-end research partner.

The deal also reflects wider consolidation across life sciences tools. Companies are moving beyond single-purpose technologies towards integrated systems that combine sequencing, analytics and other biological measurements. Scale and interoperability are becoming competitive factors as researchers demand more connected datasets.

Operational challenges remain. DNA sequencing and protein analysis rely on distinct technologies and validation standards, and integrating large datasets will require technical coordination. Regulatory scrutiny may also increase as such combined insights are applied in clinical settings.

For Illumina, however, the acquisition underlines a clear strategic direction: expanding from a sequencing specialist into a broader provider of integrated biological data platforms.